A chicken IgY can efficiently inhibit the entry and replication of SARS-CoV-2 by targeting the ACE2 binding domain in vitro

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Abstract

COVID-19 pneumonia has now spread widely in the world. Currently, no specific antiviral drugs are available. The vaccine is the most effective way to control the epidemic. Passive immune antibodies are also an effective method to prevent and cure COVID-19 pneumonia. We used the SARS-CoV-2 S receptor-binding domain (RBD) as an antigen to immunize layers in order to extract, separate, and purify SARS-CoV-2-IgY from egg yolk. SARS-CoV-2-IgY (S-IgY)can block the entry of SARS-CoV-2 into the Cells and reduce the viral load in cells. The Half effective concentration (EC 50 ) of W3-IgY (S-IgY in the third week after immunization) is 1.35 ± 0.15nM. The EC 50 of W9-IgY (S-IgY in the ninth week after immunization) is 2.76 ± 1.54 nM. When the dose of S-IgY is 55 nM, the fluorescence representing intracellular viral protein is obviously weakened in Immunofluorescence microscopy.

Results of Sars-CoV-2 /Vero E6 cell experiment confirmed that S-IgY has a strong antiviral effect on SARS-CoV-2, and its (EC 50 ) is 27.78 ±1.54 nM vs 3,259 ± 159.62 nM of Redesivir (differ > 106 times P<0 . 001 ).

S-IgY can inhibit the entry and replication of SARS-CoV-2, which is related to its targeting the ACE2 binding domain.

S-IgY is safe, efficient, stable, and easy to obtain. This antibody can be an effective tool for preventing and treating COVID-19 pneumonia.

Abstract Figure

Fig. 1.

Graphical Abstract

The figure briefly illustrates that the preparation and extraction of S-IgY and its anti-S-CoV-2 mechanism is to inhibit the entry and replication of SARS-CoV-2 by targeting the ACE2.

Article activity feed

  1. SciScore for 10.1101/2021.02.16.430255: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The second antibody was prepared by diluting HRP-labeled goat anti-chicken(Provided by ZSGB-Bio) with a ratio of 1:10000, and incubated for 1.5 h at room temperature, TBST washed the membrane for 5 times, The mixed immunoblotting chemiluminescence solution was dripped on NC membrane, incubated at room temperature for 2-3 minutes, then placed in a cassette, and the X-ray film was developed (See Fig.4). 6.
    anti-chicken(Provided by ZSGB-Bio
    suggested: None
    The cells were further incubated with the primary antibody (a monoclonal antibody against viral S protein) for 2 h, followed by incubation with the secondary antibody (Alexa 488-labeled goat anti-mouse[1:500; Abcam]).
    anti-mouse[1:500
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Forty-eight hours posttransfection, 150 μl pseudotyped VSV-ΔG bearing VSV-G protein were used to infect Vero E6 cells.
    Vero E6
    suggested: RRID:CVCL_XD71)
    Experimental Models: Organisms/Strains
    SentencesResources
    SARS-CoV-2 -IgY (dilution ratio: 1:10000) was incubated overnight by inversion method.
    SARS-CoV-2 -IgY
    suggested: None
    Software and Algorithms
    SentencesResources
    Western blot: SARS-CoV-2 S-RBD (provided by Sina Biological Company) was separated by polyacrylamide amine gel (10% separation gel+5% concentration gel) under the electrophoresis condition of 50 mA for 60 min.
    Sina
    suggested: (SINA, RRID:SCR_005067)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.